{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:44:19Z","timestamp":1792118659451,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,21]],"date-time":"2015-02-21T00:00:00Z","timestamp":1424476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1208\/s12249-015-0294-0","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T23:22:49Z","timestamp":1424388169000},"page":"1108-1121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles"],"prefix":"10.1208","volume":"16","author":[{"given":"Deepak","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Gabrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev K.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,21]]},"reference":[{"key":"294_CR1","doi-asserted-by":"crossref","DOI":"10.1002\/9781444316667","volume-title":"The treatment of epilepsy","author":"S Shorvon","year":"2009","unstructured":"Shorvon S, Perucca E, Engel Jr J. The treatment of epilepsy. 3rd ed. UK: Wiley-Blackwell West Sussex; 2009.","edition":"3"},{"key":"294_CR2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eplepsyres.2014.04.007","volume":"108","author":"HR Henney 3rd","year":"2014","unstructured":"Henney 3rd HR, Sperling MR, Rabinowicz AL, Bream G, Carrazana EJ. Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults. Epilepsy Res. 2014;108:1204\u201311.","journal-title":"Epilepsy Res"},{"key":"294_CR3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0404.2009.01170.x","volume":"120","author":"VD Ivaturi","year":"2009","unstructured":"Ivaturi VD, Riss JR, Kriel RL, Cloyd JC. Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. Acta Neurol Scand. 2009;120:353\u20137.","journal-title":"Acta Neurol Scand"},{"key":"294_CR4","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/epi.12755","volume":"55","author":"MR Sperling","year":"2014","unstructured":"Sperling MR, Haas KF, Krauss G, Seif Eddeine H, Henney 3rd HR, Rabinowicz AL, et al. Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy. Epilepsia. 2014;55:1544\u201350.","journal-title":"Epilepsia"},{"key":"294_CR5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4155\/tde.14.41","volume":"5","author":"PG Djupesland","year":"2014","unstructured":"Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv. 2014;5:709\u201333.","journal-title":"Ther Deliv"},{"key":"294_CR6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1155\/2013\/238428","volume":"2013","author":"M Masserini","year":"2013","unstructured":"Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;2013:18. doi: 10.1155\/2013\/238428 .","journal-title":"ISRN Biochem"},{"key":"294_CR7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/156720112803529828","volume":"9","author":"S Gizurarson","year":"2012","unstructured":"Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9:566\u201382.","journal-title":"Curr Drug Deliv"},{"key":"294_CR8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","volume":"127","author":"RG Thorne","year":"2004","unstructured":"Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481\u201396.","journal-title":"Neuroscience"},{"key":"294_CR9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11095-006-9534-z","volume":"23","author":"UE Westin","year":"2006","unstructured":"Westin UE, Bostr\u00f6m E, Gr\u00e5sj\u00f6 J, Hammarlund-Udenaes M, Bj\u00f6rk E. Direct nose-to-brain transfer of morphine after nasal administration to rats. Pharm Res. 2006;23:565\u201372.","journal-title":"Pharm Res"},{"key":"294_CR10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijpharm.2009.05.009","volume":"377","author":"T Shingaki","year":"2009","unstructured":"Shingaki T, Hidalgo IJ, Furubayashi T, Katsumi H, Sakane T, Yamamoto A, et al. The transnasal delivery of 5-fluorouracil to the rat brain is enhanced by acetazolamide (the inhibitor of the secretion of cerebrospinal fluid). Int J Pharm. 2009;377:85\u201391.","journal-title":"Int J Pharm"},{"key":"294_CR11","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/02652040802456726","volume":"26","author":"SB Patil","year":"2009","unstructured":"Patil SB, Sawant KK. Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery. J Microencapsul. 2009;26:432\u201343.","journal-title":"J Microencapsul"},{"key":"294_CR12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nano.2005.12.003","volume":"2","author":"CP Reis","year":"2006","unstructured":"Reis CP, Neufeld RJ, Ribeiro ANJ, Veiga F. Nanoencapsulation I. methods for preparation of drug-loaded polymeric NP. Nanomedicine Nanotech Biol Med. 2006;2:8\u201321.","journal-title":"Nanomedicine Nanotech Biol Med"},{"key":"294_CR13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Breton AL, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505\u201322.","journal-title":"J Control Release"},{"key":"294_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"A Kumari","year":"2010","unstructured":"Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B. 2010;75:1\u201318.","journal-title":"Colloids Surf B"},{"key":"294_CR15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/erm.09.15","volume":"9","author":"JM Lu","year":"2009","unstructured":"Lu JM, Wang X, Muller CM, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA based Nanotechnology. Expert Rev Mol Diagn. 2009;9:325\u201341.","journal-title":"Expert Rev Mol Diagn"},{"key":"294_CR16","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3:1377\u201397.","journal-title":"Polymers"},{"key":"294_CR17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.nano.2009.02.005","volume":"5","author":"AV Vergoni","year":"2009","unstructured":"Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine Nanotech Biol Med. 2009;5:369\u201377.","journal-title":"Nanomedicine Nanotech Biol Med"},{"key":"294_CR18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.cep.2011.05.006","volume":"50","author":"T Feczko","year":"2011","unstructured":"Feczko T, Toth J, Dosa G, Gyenis J. Influence of process conditions on the mean size of PLGA nanoparticles. Chem Eng Process. 2011;50:846\u201353.","journal-title":"Chem Eng Process"},{"key":"294_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijpharm.2004.11.027","volume":"290","author":"RM Mainardes","year":"2005","unstructured":"Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290:7\u2013144.","journal-title":"Int J Pharm"},{"key":"294_CR20","author":"D Sharma","year":"2014","unstructured":"Sharma D, Maheshwari D, Philip G, Rana R, Bhatia S, Singh M, et al. Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using Box-Behnken design: in vitro and in vivo evaluation. Biomed Res Int. 2014. doi: 10.1155\/2014\/156010 .","journal-title":"Biomed Res Int"},{"key":"294_CR21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijpharm.2006.11.061","volume":"336","author":"A Budhian","year":"2007","unstructured":"Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 2007;336:367\u201375.","journal-title":"Int J Pharm"},{"key":"294_CR22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2008.01.013","volume":"69","author":"X Song","year":"2008","unstructured":"Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm. 2008;69:445\u201353.","journal-title":"Eur J Pharm Biopharm"},{"key":"294_CR23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.colsurfa.2005.10.064","volume":"276","author":"KC Songa","year":"2006","unstructured":"Songa KC, Lee HS, Chounga IY, Choa KI, Ahnb Y, Choi EJ. The effect of type of organic phase solvents on the particle size of poly(d, l-lactide-co-glycolide) nanoparticles. Colloids Surf A. 2006;276:162\u20137.","journal-title":"Colloids Surf A"},{"key":"294_CR24","first-page":"683","volume":"6","author":"J Hao","year":"2011","unstructured":"Hao J, Fang X, Wang J, Guo F, Li F, Peng X. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine. 2011;6:683\u201392.","journal-title":"Int J Nanomedicine"},{"key":"294_CR25","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1016\/j.actbio.2011.07.025","volume":"7","author":"U Seju","year":"2011","unstructured":"Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 2011;7:4169\u201376.","journal-title":"Acta Biomater"},{"key":"294_CR26","unstructured":"Fessi et al. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. US Patent 1992; 5,118,528."},{"key":"294_CR27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejps.2004.09.011","volume":"24","author":"U Bilati","year":"2005","unstructured":"Bilati U, Emann EA, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24:67\u201375.","journal-title":"Eur J Pharm Sci"},{"key":"294_CR28","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1039\/C0SM00862A","volume":"7","author":"S Hornig","year":"2011","unstructured":"Hornig S, Heinze T, Becer CR, Schubertb US. Nanoprecipitation and nanoformulation of polymers: from history to powerful possibilities beyond poly(lactic acid). Soft Matter. 2011;7:1581\u20138.","journal-title":"Soft Matter"},{"key":"294_CR29","unstructured":"USP30-NF25, Diazepam, 1912."},{"key":"294_CR30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.nano.2010.02.002","volume":"6","author":"B Semete","year":"2010","unstructured":"Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Jan V, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine Nanotech Biol Med. 2010;6:662\u201371.","journal-title":"Nanomedicine Nanotech Biol Med"},{"key":"294_CR31","doi-asserted-by":"crossref","unstructured":"El-Ansary A, Al-Daihan S. On the toxicity of therapeutically used nanoparticles: an overview. J Toxicol 2009; 754810. doi: 10.1155\/2009\/754810 .","DOI":"10.1155\/2009\/754810"},{"key":"294_CR32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.taap.2008.06.026","volume":"232","author":"R Lei","year":"2008","unstructured":"Lei R, Wu C, Yang B, Ma H, Shi C, Wang Q, et al. Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: a rapid in vivo screening method for nanotoxicity. Toxicol Appl Pharmacol. 2008;232:292\u2013301.","journal-title":"Toxicol Appl Pharmacol"},{"key":"294_CR33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jps.23350","volume":"102","author":"EVR Campos","year":"2013","unstructured":"Campos EVR, Melo NFSD, Guilherme VA, Paula ED, Rosa AH, ArauJo DRD, et al. Preparation and characterization of poly(\u03b5-Caprolactone) nanospheres containing the local anesthetic lidocaine. J Pharm Sci. 2013;102:215\u201326.","journal-title":"J Pharm Sci"},{"issue":"7","key":"294_CR34","doi-asserted-by":"crossref","first-page":"e32616","DOI":"10.1371\/journal.pone.0032616","volume":"12","author":"A Mathew","year":"2012","unstructured":"Mathew A, Takahiro F, Yutaka N, Takashi H, Hisao M, Yasuhiko Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer\u2019s disease. PLoS ONE. 2012;12(7):e32616.","journal-title":"PLoS ONE"},{"key":"294_CR35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/0975-7406.120081","volume":"5","author":"M Snehalatha","year":"2013","unstructured":"Snehalatha M, Kolachina V, Saha RN, Babbar AK, Sharma N, Sharma RK. Enhanced tumor uptake, biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton\u2019s lymphoma tumor bearing mice. J Pharm Bioallied Sci. 2013;5:38\u201345.","journal-title":"J Pharm Bioallied Sci"},{"key":"294_CR36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860500246217","volume":"13","author":"TK Vyas","year":"2005","unstructured":"Vyas TK, Babbar AK, Sharma RK, Misra A. Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J Drug Target. 2005;13:317\u201324.","journal-title":"J Drug Target"},{"key":"294_CR37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","volume":"358","author":"M Kumar","year":"2008","unstructured":"Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm. 2008;358:285\u201391.","journal-title":"Int J Pharm"},{"key":"294_CR38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/10611860802476504","volume":"16","author":"M Kumar","year":"2008","unstructured":"Kumar M, Misra A, Mishra AK, Mishra P, Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target. 2008;16:806\u201314.","journal-title":"J Drug Target"},{"key":"294_CR39","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.2147\/IJN.S35329","volume":"7","author":"S Alam","year":"2012","unstructured":"Alam S, Khan ZI, Mustafa G, Kumar M, Islam F, Bhatnagar A, et al. Development and evaluation of thymoquinone- encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine. 2012;7:5705\u201318.","journal-title":"Int J Nanomedicine"},{"key":"294_CR40","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jps.20094","volume":"93","author":"J Panyam","year":"2004","unstructured":"Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA\/PLA nanoparticles. J Pharm Sci. 2004;93:1804\u201314.","journal-title":"J Pharm Sci"},{"key":"294_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-9-S3-S5","volume":"9","author":"LR Hanson","year":"2008","unstructured":"Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9:1\u20134.","journal-title":"BMC Neurosci"},{"key":"294_CR42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12034-012-0313-7","volume":"35","author":"RK Averineni","year":"2012","unstructured":"Averineni RK, Shavi GV, Gurram AK, Deshpande PB, Arumugam K, Maliyakkal N, et al. PLGA 50:50 nanoparticles of paclitaxel: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation. Bull Mater Sci. 2012;35:319\u201326.","journal-title":"Bull Mater Sci"},{"key":"294_CR43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/BF02707148","volume":"17","author":"JW Nah","year":"2006","unstructured":"Nah JW, Y-Il J, Koh JJ. Drug release from nanoparticles of poly(dl-lactide-co-glycolide). Korean J Chem Eng. 2006;17:230\u20136.","journal-title":"Korean J Chem Eng"},{"key":"294_CR44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.eplepsyres.2012.07.018","volume":"103","author":"V Ivaturi","year":"2013","unstructured":"Ivaturi V, Kriel R, Brundage R, Gordon L, Mansbach H, Cloyd J. Bioavailability of intranasal vs. rectal diazepam. Epilepsy Res. 2013;103:254\u201361.","journal-title":"Epilepsy Res"},{"key":"294_CR45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.eplepsyres.2013.02.018","volume":"105","author":"SK Agarwal","year":"2013","unstructured":"Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res. 2013;105:362\u20137.","journal-title":"Epilepsy Res"},{"key":"294_CR46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2217\/17435889.2.2.219","volume":"2","author":"T Betancourt","year":"2007","unstructured":"Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine. 2007;2:219\u201332.","journal-title":"Nanomedicine"},{"key":"294_CR47","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1166\/asl.2014.5520","volume":"20","author":"D Sharma","year":"2014","unstructured":"Sharma D, Gabrani R, Sharma SK, Ali J, Dang S. Development of midazolam loaded PLGA nanoparticles for treatment of status epilepticus. Adv Sci Lett. 2014;20:1526\u201330.","journal-title":"Adv Sci Lett"},{"key":"294_CR48","first-page":"9","volume":"3","author":"RK Prajapati","year":"2011","unstructured":"Prajapati RK, Mahajan HS, Surana SJ. PLGA based mucoadhesive microspheres for nasal delivery: in vitro\/ex vivo studies. Indian J Novel Drug Deliv. 2011;3:9\u201316.","journal-title":"Indian J Novel Drug Deliv"},{"key":"294_CR49","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3109\/03639049809108571","volume":"24","author":"D Quintanar-Guerrero","year":"1998","unstructured":"Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24:1113\u201328.","journal-title":"Drug Dev Ind Pharm"},{"key":"294_CR50","first-page":"361","volume":"4","author":"B Sylaja","year":"2012","unstructured":"Sylaja B, Srinivasan S. Experimental and theoretical investigation of spectroscopic properties of diazepam. Int J Chem Tech Res. 2012;4:361\u201376.","journal-title":"Int J Chem Tech Res"},{"key":"294_CR51","first-page":"523","volume":"42","author":"RM Mainardes","year":"2006","unstructured":"Mainardes RM, Gremiao MPD, Evangelista RC. Thermoanalytical study of praziquantel-loaded PLGA nanoparticles. Braz J Pharm Sci. 2006;42:523\u201330.","journal-title":"Braz J Pharm Sci"},{"key":"294_CR52","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/cancers5031020","volume":"5","author":"M van Woensel","year":"2013","unstructured":"van Woensel M, Wauthoz N, Rosi\u00e8re R, Amighi K, Mathieu V, Lefranc F, et al. Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers. 2013;5:1020\u201348.","journal-title":"Cancers"},{"key":"294_CR53","first-page":"3867","volume":"29","author":"A Mukerjee","year":"2009","unstructured":"Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29:3867\u201376.","journal-title":"Anticancer Res"},{"key":"294_CR54","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1208\/s12249-009-9329-8","volume":"10","author":"G Sharma","year":"2009","unstructured":"Sharma G, Mishra AK, Mishra P, Misra A. Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies. AAPS PharmSciTech. 2009;10:1321\u201330.","journal-title":"AAPS PharmSciTech"},{"key":"294_CR55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3109\/1061186X.2011.558090","volume":"19","author":"RJ Babu","year":"2011","unstructured":"Babu RJ, Dayal PP, Pawar K, Singh M. Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J Drug Target. 2011;19:731\u201340.","journal-title":"J Drug Target"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-015-0294-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-015-0294-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-015-0294-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T03:33:22Z","timestamp":1559619202000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-015-0294-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,21]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["294"],"URL":"https:\/\/doi.org\/10.1208\/s12249-015-0294-0","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,21]]}}}